Biological Assembly 1  

 3D View: Structure | Electron Density | Ligand Interaction

Standalone Viewers  
Protein Workshop | Ligand Explorer

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Hetero 3-mer - ABC 

Biological assembly 1 assigned by authors.

Biological Assembly 2  

 3D View: Structure | Electron Density | Ligand Interaction

Standalone Viewers  
Protein Workshop | Ligand Explorer

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Hetero 3-mer - ABC 

Biological assembly 2 assigned by authors.

Macromolecule Content

• Total Structure Weight: 100574.88 
• Atom Count: 6860 
• Residue Count: 928 
• Unique protein chains: 3

3IXT

Crystal Structure of Motavizumab Fab Bound to Peptide Epitope

• DOI: 10.2210/pdb3IXT/pdb

• Classification: IMMUNE SYSTEM
• Organism(s): Human respiratory syncytial virus A (strain A2)
• Expression System: Homo sapiens


• Deposited: 2009-09-04 Released: 2010-01-19 
• Deposition Author(s): McLellan, J.S., Chen, M., Kim, A., Yang, Y., Graham, B.S., Kwong, P.D.

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 2.75 Å
• R-Value Free: 0.274 
• R-Value Work: 0.213 

Literature

Structural basis of respiratory syncytial virus neutralization by motavizumab.

McLellan, J.S., Chen, M., Kim, A., Yang, Y., Graham, B.S., Kwong, P.D.

(2010) Nat.Struct.Mol.Biol. 17: 248-250

• PubMed: 20098425 
• DOI: 10.1038/nsmb.1723


• PubMed Abstract: 
  

Motavizumab is approximately tenfold more potent than its predecessor, palivizumab (Synagis), the FDA-approved monoclonal antibody used to prevent respiratory syncytial virus (RSV) infection. The structure of motavizumab in complex with a 24-residue peptide corresponding to its epitope on the RSV fusion (F) glycoprotein reveals the structural basis for this greater potency. Modeling suggests that motavizumab recognizes a different quaternary configuration of the F glycoprotein than that observed in a homologous structure.

---

Organizational Affiliation: 

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.

Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details
Motavizumab Fab light chain	L, B	213	N/A	Mutation(s): 0
Protein Feature View is not available: No corresponding UniProt sequence found.

Entity ID: 2
Molecule	Chains	Sequence Length	Organism	Details
Motavizumab Fab heavy chain	H, A	225	N/A	Mutation(s): 0
Protein Feature View is not available: No corresponding UniProt sequence found.

Entity ID: 3
Molecule	Chains	Sequence Length	Organism	Details
Fusion glycoprotein F1	P, C	26	Human respiratory syncytial virus A (strain A2)	Mutation(s): 0  Gene Names: F
Find proteins for P03420 (Human respiratory syncytial virus A (strain A2)) Go to UniProtKB:  P03420

Small Molecules

Ligands 1 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram & Interactions
EDO	A, C, P	1,2-ETHANEDIOL ETHYLENE GLYCOL C2 H6 O2 LYCAIKOWRPUZTN-UHFFFAOYSA-N

Modified Residues  2 Unique
ID	Chains	Type	Formula	2D Diagram	Parent
NH2	C, P	NON-POLYMER	H2 N		--
ACE	C, P	NON-POLYMER	C2 H4 O		--

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 2.75 Å
• R-Value Free: 0.274 
• R-Value Work: 0.213 
• Space Group: P 4₃ 2₁ 2

Unit Cell:

Length (Å)	Angle (°)
a = 90.752	α = 90.00
b = 90.752	β = 90.00
c = 232.057	γ = 90.00

Software Package:

Software Name	Purpose
PHASER	phasing
PHENIX	refinement
HKL-2000	data reduction
HKL-2000	data scaling

Structure Validation

Entry History 

Deposition Data

• Deposited Date: 2009-09-04 
• Released Date: 2010-01-19 
• Deposition Author(s): McLellan, J.S., Chen, M., Kim, A., Yang, Y., Graham, B.S., Kwong, P.D.

Revision History 

• Version 1.0: 2010-01-19
  Type: Initial release
• Version 1.1: 2011-07-13
  Type: Source and taxonomy, Version format compliance